Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Non-Current Assets: 2023-2025

Historic Non-Current Assets for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $16.0 million.

  • Inhibrx Biosciences' Non-Current Assets rose 6.17% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 6.17%. This contributed to the annual value of $20.4 million for FY2024, which is 62.50% up from last year.
  • Per Inhibrx Biosciences' latest filing, its Non-Current Assets stood at $16.0 million for Q3 2025, which was down 11.60% from $18.2 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Non-Current Assets ranged from a high of $20.4 million in Q4 2024 and a low of $12.5 million during Q4 2023.
  • In the last 3 years, Inhibrx Biosciences' Non-Current Assets had a median value of $16.4 million in 2024 and averaged $16.8 million.
  • Data for Inhibrx Biosciences' Non-Current Assets shows a peak YoY skyrocketed of 62.50% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Non-Current Assets (Quarterly) stood at $12.5 million in 2023, then soared by 62.50% to $20.4 million in 2024, then rose by 6.17% to $16.0 million in 2025.
  • Its Non-Current Assets was $16.0 million in Q3 2025, compared to $18.2 million in Q2 2025 and $19.3 million in Q1 2025.